Skip to content

Study · Animal study (in vivo) · mouse · 2008

7 results

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D

Gastroenterology17 Oct 2007Cited by 99 (Europe PMC)

PMID18061177 (opens in a new tab)PMCIDPMC2431115 (opens in a new tab)DOI10.1053/j.gastro.2007.10.026 (opens in a new tab)PepBankPUB-18061177
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, oral KPV reduced the incidence of dextran sodium sulfate-induced colitis.

    In plain wordsIn mice, KPV given by mouth reduced how often colitis developed after a colitis-inducing agent.

    Peptide
    KPV
    Outcome
    DecreaseIncidence of DSS-induced colitis
    Study

    mousen: not reported in source

    DSS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression.
    1 context sentence
    Summary · context
    KPV was added to drinking water and inflammation was assessed at the histologic level and by proinflammatory cytokine mRNA expression.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, oral KPV reduced the incidence of TNBS-induced colitis.

    In plain wordsIn mice, KPV given by mouth reduced how often colitis developed after a colitis-inducing agent.

    Peptide
    KPV
    Outcome
    DecreaseIncidence of TNBS-induced colitis
    Study

    mousen: not reported in source

    TNBS-induced colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression.
    1 context sentence
    Summary · context
    KPV was added to drinking water and inflammation was assessed at the histologic level and by proinflammatory cytokine mRNA expression.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS- or TNBS-induced colitis, oral KPV decreased expression of pro-inflammatory cytokines.

    In plain wordsIn mice with colitis, KPV given by mouth lowered the activity of genes for inflammatory signals.

    Peptide
    KPV
    Outcome
    DecreasePro-inflammatory cytokine mRNA expression in colitis
    Study

    mousen: not reported in source

    DSS- and TNBS-induced colitis
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression.
    1 context sentence
    Summary · context
    KPV was added to drinking water and inflammation was assessed at the histologic level and by proinflammatory cytokine mRNA expression.
  4. 04LabIn vitro (cells)Mechanism

    In human intestinal epithelial and T cells stimulated with cytokines, nanomolar KPV inhibited activation of the NF-kappaB pathway.

    In plain wordsIn human cells, very low concentrations of KPV blocked activation of an inflammation pathway (NF-kappaB).

    Peptide
    KPV
    Outcome
    DecreaseNF-kappaB activation
    Study

    humann: not reported in source

    Caco2-BBE, HT29-Cl.19A and Jurkat cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    nanomolar concentrationsAs given in this study (human).

    Source sentences

    Summary
    Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion.
    1 context sentence
    Summary · context
    Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV.
  5. 05LabIn vitro (cells)Mechanism

    In human intestinal epithelial and T cells stimulated with cytokines, nanomolar KPV inhibited activation of MAP kinase signaling.

    In plain wordsIn human cells, very low concentrations of KPV blocked activation of an inflammation pathway (MAP kinase).

    Peptide
    KPV
    Outcome
    DecreaseMAP kinase activation
    Study

    humann: not reported in source

    Caco2-BBE, HT29-Cl.19A and Jurkat cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    nanomolar concentrationsAs given in this study (human).

    Source sentences

    Summary
    Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion.
    1 context sentence
    Summary · context
    Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV.
  6. 06LabIn vitro (cells)Efficacy outcome

    In human intestinal epithelial and T cells stimulated with cytokines, nanomolar KPV reduced secretion of pro-inflammatory cytokines.

    In plain wordsIn human cells, very low concentrations of KPV reduced release of inflammatory signals.

    Peptide
    KPV
    Outcome
    DecreasePro-inflammatory cytokine secretion
    Study

    humann: not reported in source

    Caco2-BBE, HT29-Cl.19A and Jurkat cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    nanomolar concentrationsAs given in this study (human).

    Source sentences

    Summary
    Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion.
    1 context sentence
    Summary · context
    Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV.
  7. 07LabIn vitro (cells)Mechanism

    In human intestinal epithelial and immune cells, KPV acted via the PepT1 transporter.

    In plain wordsIn human cells, KPV worked through a transporter called PepT1.

    Peptide
    KPV
    Outcome
    Not applicableRole of PepT1 in KPV anti-inflammatory action
    Study

    humann: not reported in source

    Caco2-BBE, HT29-Cl.19A and Jurkat cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that KPV acts via PepT1 expressed in immune and intestinal epithelial cells.
    1 context sentence
    Summary · context
    Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.